collection
MENU ▼
Read by QxMD icon Read
search

CKD Biomarkers

shared collection
153 papers 25 to 100 followers
By Isabel Acosta-Ochoa Nephrology senior staff. Valladolid. Spain
https://www.readbyqxmd.com/read/29471407/plasma-copeptin-as-a-predictor-of-kidney-disease
#1
Sofia Enhörning, Anders Christensson, Olle Melander
Background: Plasma copeptin, a marker of vasopressin, is associated with renal function decline in the general population. Our aim was to study the links between elevated copeptin and future risk of kidney disease. Methods: Copeptin was measured in a sample of the Malmö Preventive Project (MPP) Reinvestigation (n = 5158) and in the Malmö Diet and Cancer Cardiovascular Cohort (MDC-CC) (n = 5162). According to national registers, 89 subjects in MPP and 180 in MDC-CC developed chronic kidney disease (CKD) during follow-up (8...
February 16, 2018: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29398328/relation-of-asymmetrical-dimethylarginine-levels-with-renal-outcomes-in-hypertensive-patients-with-and-without-type-2-diabetes-mellitus
#2
Cristina B Triches, Marie Quinto, Saurus Mayer, Marcelo Batista, Maria Teresa Zanella
AIM: The aim of the study was to evaluate the association between high plasma ADMA levels, a biomarker of endothelial dysfunction, with the progression of albuminuria and chronic kidney disease (CKD) in hypertensive patients, with and without type 2 diabetes mellitus. METHODS: We successfully contacted 213 of 644 patients who had been evaluated between 2004 and 2005 and for whom basal data were available. After the exclusion of 51 patients, 162 hypertensive patients who were free from albuminuria were stratified into the following 4 groups according to the presence of diabetes and plasma ADMA percentiles: general hypertensive patients with high levels of plasma ADMA (>P4 or ADMA > 0...
December 21, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29339356/kidney-biomarkers-and-decline-in-egfr-in-patients-with-type-2-diabetes
#3
Katherine G Garlo, William B White, George L Bakris, Faiez Zannad, Craig A Wilson, Stuart Kupfer, Muthiah Vaduganathan, David A Morrow, Christopher P Cannon, David M Charytan
BACKGROUND AND OBJECTIVES: Biomarkers may improve identification of individuals at risk of eGFR decline who may benefit from intervention or dialysis planning. However, available biomarkers remain incompletely validated for risk stratification and prediction modeling. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined serum cystatin C, urinary kidney injury molecule-1 (uKIM-1), and urinary neutrophil gelatinase-associated lipocalin (UNGAL) in 5367 individuals with type 2 diabetes mellitus and recent acute coronary syndromes enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial...
January 16, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/29333147/novel-filtration-markers-for-gfr-estimation
#4
Amy B Karger, Lesley A Inker, Josef Coresh, Andrew S Levey, John H Eckfeldt
Creatinine-based glomerular filtration rate estimation (eGFRcr) has been improved and refined since the 1970s through both the Modification of Diet in Renal Disease (MDRD) Study equation in 1999 and the CKD Epidemiology Collaboration (CKD-EPI) equation in 2009, with current clinical practice dependent primarily on eGFR for accurate assessment of GFR. However, researchers and clinicians have recognized limitations of relying on creatinine as the only filtration marker, which can lead to inaccurate GFR estimates in certain populations due to the influence of non-GFR determinants of serum or plasma creatinine...
December 2017: EJIFCC
https://www.readbyqxmd.com/read/29281176/the-impact-of-the-glomerular-filtration-rate-on-the-human-plasma-proteome
#5
Anders Christensson, Jessica A Ash, Robert K DeLisle, Fraser W Gaspar, Rachel Ostroff, Anders Grubb, Veronica Lindström, Laila Bruun, Steve A Williams
PURPOSE: The application of proteomics in chronic kidney disease (CKD) can potentially uncover biomarkers and pathways that are predictive of disease. EXPERIMENTAL DESIGN: Within this context, this study examined the relationship between the human plasma proteome and glomerular filtration rate (GFR) as measured by iohexol clearance in a cohort from Sweden (N = 389; GFR range: 8 - 100 mL/min/1.73m2 ). A total of 2893 proteins were quantified using a modified aptamer assay...
December 27, 2017: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/29240457/urinary-peptidomics-in-kidney-disease-and-drug-research
#6
Magdalena Krochmal, Joost P Schanstra, Harald Mischak
Due to its close connection with the renal system, urine is considered a valuable source of information in kidney disease research. Peptidomics methods focus on the discovery of endogenous peptides, given their wide range of biological functions and diagnostic and therapeutic potential. Representing a non-invasive and sensitive method, technological prospects of urinary peptidomics should be evaluated in the context of drug discovery and research. Areas covered: This review describes urinary peptidomics with focus on its application in drug research in the field of kidney diseases...
December 19, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29228604/bcl-3-is-a-novel-biomarker-of-renal-fibrosis-in-chronic-kidney-disease
#7
Ran Chen, Lunshan Wang, Sanhong Liu, Xi Chen, Yiming Hu, Hanshao Liu, Haohao Zhang, Yuhang Jiang, Qi Wang, Deji Ye, Lingling Li, Dandan Liu, Xiaorong Pan, Lixin Wei, Xuemei Li, Xiaoren Zhang
Progressive renal fibrosis in chronic kidney disease (CKD) greatly contributes to end-stage renal failure and is associated with high mortality. The identification of renal fibrosis biomarkers for the diagnosis and the monitoring of disease progression in CKD is urgently needed. Whole-transcriptomic analysis of renal tissues in a unilateral ureteral obstruction (UUO) mouse model revealed that the mRNA level of Bcl-3, an atypical member of the IκB family, was induced 6.3-fold 2 days after UUO. Compared with renal tissues in sham-operated mice, increases in Bcl-3 mRNA and protein in the renal tissues in the UUO model were accompanied with increases in other markers of renal fibrosis, including human epididymis protein 4 (HE4), a recently identified biomarker of renal fibrosis...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29234020/from-discovery-to-translation-characterization-of-c-mannosyltryptophan-and-pseudouridine-as-markers-of-kidney-function
#8
Peggy Sekula, Katja Dettmer, Franziska C Vogl, Wolfram Gronwald, Lisa Ellmann, Robert P Mohney, Kai-Uwe Eckardt, Karsten Suhre, Gabi Kastenmüller, Peter J Oefner, Anna Köttgen
Using a non-targeted metabolomics platform, we recently identified C-mannosyltryptophan and pseudouridine as non-traditional kidney function markers. The aims of this study were to obtain absolute concentrations of both metabolites in blood and urine from individuals with and without CKD to provide reference ranges and to assess their fractional excretions (FE), and to assess the agreement with their non-targeted counterparts. In individuals without/with CKD, mean plasma and urine concentrations for C-mannosyltryptophan were 0...
December 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29229941/urinary-endotrophin-predicts-disease-progression-in-patients-with-chronic-kidney-disease
#9
Daniel Guldager Kring Rasmussen, Anthony Fenton, Mark Jesky, Charles Ferro, Peter Boor, Martin Tepel, Morten Asser Karsdal, Federica Genovese, Paul Cockwell
Renal fibrosis is the central pathogenic process in progression of chronic kidney disease (CKD). Collagen type VI (COL VI) is upregulated in renal fibrosis. Endotrophin is released from COL VI and promotes pleiotropic pro-fibrotic effects. Kidney disease severity varies considerably and accurate information regarding CKD progression may improve clinical decisions. We tested the hypothesis that urinary endotrophin derived during COL VI deposition in fibrotic human kidneys is a marker for progression of CKD in the Renal Impairment in Secondary Care (RIISC) cohort, a prospective observational study of 499 CKD patients...
December 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29208969/association-of-kidney-fibrosis-with-urinary-peptides-a-path-towards-non-invasive-liquid-biopsies
#10
Pedro Magalhães, Martin Pejchinovski, Katerina Markoska, Miroslaw Banasik, Marian Klinger, Dominika Švec-Billá, Ivan Rychlík, Merita Rroji, Arianna Restivo, Giovambattista Capasso, Flaviu Bob, Adalbert Schiller, Alberto Ortiz, Maria Vanessa Perez-Gomez, Pablo Cannata, Maria Dolores Sanchez-Niño, Radomir Naumovic, Voin Brkovic, Momir Polenakovic, William Mullen, Antonia Vlahou, Petra Zürbig, Lars Pape, Franco Ferrario, Colette Denis, Goce Spasovski, Harald Mischak, Joost P Schanstra
Chronic kidney disease (CKD) is a prevalent cause of morbidity and mortality worldwide. A hallmark of CKD progression is renal fibrosis characterized by excessive accumulation of extracellular matrix (ECM) proteins. In this study, we aimed to investigate the correlation of the urinary proteome classifier CKD273 and individual urinary peptides with the degree of fibrosis. In total, 42 kidney biopsies and urine samples were examined. The percentage of fibrosis per total tissue area was assessed in Masson trichrome stained kidney tissues...
December 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29190600/hyaluronic-acid-as-a-new-biomarker-to-differentiate-acute-kidney-injury-from-chronic-kidney-disease
#11
Davut Akin, Sehmus Ozmen, Mehmet Emin Yilmaz
INTRODUCTION: It may be difficult to differentiate acute kidney injury from chronic kidney disease in patients with no past medical reports of kidney function. This study aimed to investigate the role of serum hyaluronic acid (HA), which is known as a marker of fibrosis, in differential diagnosis of kidney failure. MATERIALS AND METHODS: A total of 90 patients (52 women and 38 mne) admitted to our renal unit with uremia for the first time were included. Serum HA level was measured...
November 2017: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/29172403/circulating-renalase-predicts-all-cause-mortality-and-renal-outcomes-in-patients-with-advanced-chronic-kidney-disease
#12
Seon Ha Baek, Ran-Hui Cha, Shin Wook Kang, Cheol Whee Park, Dae Ryong Cha, Sung Gyun Kim, Sun Ae Yoon, Sejoong Kim, Sang-Youb Han, Jung Hwan Park, Jae Hyun Chang, Chun Soo Lim, Yon Su Kim, Ki Young Na
Background/Aims: Patients with chronic kidney disease (CKD) have been found to show markedly increased rates of end-stage renal disease, major adverse cardiovascular and cerebrovascular events (MACCEs), and mortality. Therefore, new biomarkers are required for the early detection of such clinical outcomes in patients with CKD. We aimed to determine whether the level of circulating renalase was associated with CKD progression, MACCEs, and all-cause mortality, using data from a prospective randomized controlled study, Kremezin STudy Against Renal disease progression in Korea (K-STAR; NCT 00860431)...
November 29, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29181712/exosomes-and-microvesicles-in-normal-physiology-pathophysiology-and-renal-diseases
#13
REVIEW
Anne-Lie Ståhl, Karl Johansson, Maria Mossberg, Robin Kahn, Diana Karpman
Extracellular vesicles are cell-derived membrane particles ranging from 30 to 5,000 nm in size, including exosomes, microvesicles, and apoptotic bodies. They are released under physiological conditions, but also upon cellular activation, senescence, and apoptosis. They play an important role in intercellular communication. Their release may also maintain cellular integrity by ridding the cell of damaging substances. This review describes the biogenesis, uptake, and detection of extracellular vesicles in addition to the impact that they have on recipient cells, focusing on mechanisms important in the pathophysiology of kidney diseases, such as thrombosis, angiogenesis, tissue regeneration, immune modulation, and inflammation...
November 27, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/29148856/novel-applications-for-serum-procalcitonin-testing-in-clinical-practice
#14
Justin J Choi, Matthew W McCarthy
Procalcitonin has emerged as a reliable marker of acute bacterial infection in hospitalized patients and the assay has recently been incorporated into several clinical algorithms to reduce antimicrobial overuse, but its use in patients with end-organ dysfunction is controversial. Areas covered: In this review, the authors examine what is known about procalcitonin testing in patients with organ dysfunction, including those with end-stage renal disease, congestive heart failure, chronic obstructive pulmonary disease, and cirrhosis, and explore how the assay is now being used in the management of non-infectious diseases...
January 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/29142970/cardiovascular-disease-biomarkers-and-supar-in-predicting-decline-in-renal-function-a-prospective-cohort-study
#15
Salim S Hayek, Yi-An Ko, Mosaab Awad, Hina Ahmed, Brandon Gray, Kareem Mohammed Hosny, Hiroshi Aida, Melissa J Tracy, Changli Wei, Sanja Sever, Jochen Reiser, Arshed A Quyyumi
Introduction: Soluble urokinase-type plasminogen activator receptor (suPAR) strongly predicts outcomes and incident chronic kidney disease (CKD) in patients with cardiovascular disease (CVD). Whether the association between suPAR and CKD is a reflection of its overall association with chronic inflammation and poor CVD outcomes is unclear. We examined whether CVD biomarkers, including high-sensitivity C-reactive protein (hs-CRP), fibrin-degradation products (FDPs), heat-shock protein 70 (HSP-70), and high-sensitivity troponin I (hs-TnI) were associated with a decline in kidney function in the Emory Cardiovascular Biobank cohort, in which suPAR levels were shown to be predictive of both incident CKD and CVD outcomes...
May 2017: KI Reports
https://www.readbyqxmd.com/read/29106632/cost-effectiveness-of-screening-type-2-diabetes-patients-for-chronic-kidney-disease-progression-with-the-ckd273-urinary-peptide-classifier-as-compared-to-urinary-albumin-excretion
#16
Elena Critselis, Antonia Vlahou, Vianda S Stel, Rachael L Morton
Background: In type 2 diabetes mellitus (T2DM) patients, chronic kidney disease (CKD) progression may occur without detectable changes in urinary albumin excretion (UAE) rate. A new urinary peptide classifier (CKD273) has exhibited greater ability to detect CKD progression, however, its cost-effectiveness remains unknown. This study evaluated the cost-effectiveness of screening for CKD progression with the CKD273 classifier, as compared to UAE, in diabetic patients. Methods: A decision-analytic Markov model was developed to estimate costs and health outcomes [including overall survival and quality-adjusted life years (QALYs)] from a health system perspective for adopting a new annual screening strategy based on the CKD273 classifier as compared to annual UAE-based screening in a hypothetical cohort of T2DM patients...
July 3, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/29092736/the-associations-of-bmi-1-with-progression-of-glomerular-chronic-kidney-disease%C3%A2
#17
Xiaoxia Yang, Ming Bai, Xiaoxuan Ning, Feng Ma, Limin Liu, Ting Liu, Minna Liu, Hanmin Wang, Shiren Sun
BACKGROUND: Our previous studies indicated that Bmi-1 plays an important role in hypoxia-induced tubular epithelial-mesenchymal transition and the development of kidney fibrosis in cellular and animal models. However, circulating Bmi-1 levels in human chronic kidney disease (CKD) and their relation to progression remains unknown. MATERIALS AND METHODS: We conducted a post-hoc analysis of a prospective cohort study. The blood samples and clinical data of 230 patients with glomerular CKD and 67 healthy adults were prospectively collected between January 2010 and June 2012...
October 26, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/29093371/-identification-of-biomarkers-for-tubular-injury-and-interstitial-fibrosis-in-chronic-kidney-disease
#18
Shunsaku Nakagawa
 In chronic kidney disease (CKD), progressive nephron loss causes tubulointerstitial fibrosis and progressive tubular injury. Recent identification of the major cell populations of myofibroblast precursors in the kidney has enabled us to dissect the fibrogenic process after tubular injury. Kidney pericytes are a possible precursor of myofibroblasts, and may be promising targets for treating fibrogenesis. Our recent studies have shown that pericytes activate Toll-like receptor (TLR) 2/4- and myeloid differentiation primary response 88 (MyD88)-dependent proinflammatory signaling in response to renal tubular injury...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/29100030/plasma-biomarker-discovery-for-early-chronic-kidney-disease-diagnosis-based-on-chemometric-approaches-using-lc-qtof-targeted-metabolomics-data
#19
S Benito, A Sánchez-Ortega, N Unceta, J J Jansen, G Postma, F Andrade, L Aldámiz-Echevarria, L M C Buydens, M A Goicolea, R J Barrio
Chronic kidney disease (CKD) is a progressive pathological condition in which renal function deteriorates in time. The first diagnosis of CKD is often carried out in general care attention by general practitioners by means of serum creatinine (CNN) levels. However, it lacks sensitivity and thus, there is a need for new robust biomarkers to allow the detection of kidney damage particularly in early stages. Multivariate data analysis of plasma concentrations obtained from LC-QTOF targeted metabolomics method may reveal metabolites suspicious of being either up-regulated or down-regulated from urea cycle, arginine methylation and arginine-creatine metabolic pathways in CKD pediatrics and controls...
October 29, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29026688/establishing-the-presence-or-absence-of-chronic-kidney-disease-uses-and-limitations-of-formulas-estimating-the-glomerular-filtration-rate
#20
REVIEW
Ahmed Alaini, Deepak Malhotra, Helbert Rondon-Berrios, Christos P Argyropoulos, Zeid J Khitan, Dominic S C Raj, Mark Rohrscheib, Joseph I Shapiro, Antonios H Tzamaloukas
The development of formulas estimating glomerular filtration rate (eGFR) from serum creatinine and cystatin C and accounting for certain variables affecting the production rate of these biomarkers, including ethnicity, gender and age, has led to the current scheme of diagnosing and staging chronic kidney disease (CKD), which is based on eGFR values and albuminuria. This scheme has been applied extensively in various populations and has led to the current estimates of prevalence of CKD. In addition, this scheme is applied in clinical studies evaluating the risks of CKD and the efficacy of various interventions directed towards improving its course...
September 26, 2017: World Journal of Methodology
label_collection
label_collection
4777
1
2
2017-10-15 10:11:12
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"